Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Actuate Therapeutics Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03678883CT.gov 9-ING-41 in Patients With Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT03463265CT.gov Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
NCT02986178CT.gov Lerapolturev in Recurrent Malignant Glioma | — | Completed | — | — | — |
NCT01989052CT.gov Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lomustine (this asset) | Actuate Therapeutics Inc. | P2 | B · 61 |
| Irinotecan | Kailin Yang, MD, PhD | P2 | BB |
| Marizomib | Aadi Bioscience, Inc. | P2 | BB |
| Valaciclovir | Trogenix ltd | P2 | BB |
| Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide | Oblato, Inc. | P2 | BB |
| Lenalidomide | M.D. Anderson Cancer Center | P2 | B |
| Nogitecan | Jeffrey N. Bruce | P2 | B |
| Nivolumab | University of Florida | P2 | B |
| Chlorotoxin | TransMolecular | P2 | B |
+42 more in the Malignant Glioma cohort
Other indications for Lomustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P3 | BB · 68 |
| Glioblastoma | — | P3 | BB · 67 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lomustine in Malignant Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lomustine-malignant-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →